Annie Kennedy
Showing 1–2 of 2 transcripts.
- Milken Institute6h 47m
Celebrating America's Patient Advocates: Advancing the Next Era of Innovation and Access
David Trulio, Kristen Schneemann, Dr. Francis Collins, Brian Wallach, Sandra Abravea, Margaret Anderson, Debbie, Erin, Ellen, Peter, Aaron, Ramy Pierini, Eric Racine, Dr. Wayne Frederick, Annie Kennedy, Adrienne Shapiro, Sean Martin, Leah Howard, Jean Wright, Dominica Kovacs, Roy Swartz, Dr. Uche Blackstock, Kristen Dahlgren, Darius Tahir, Donna Cryer, Angie Davis, Natasha Fitter, Randy Ruta, Bill Lawrence, Michael Hund, Dr. Roland Illing, Emily Taylor, Sarah, Isaiah, Christine
The Milken Institute convened patient advocates, researchers, and industry leaders to mark its 250th anniversary by formalizing a transition from token consultation to active partnership in healthcare innovation. The gathering showcased significant milestones such as the $1.6 billion ALS funding mobilization and the Crohn's & Colitis Foundation's use of consented patient data to accelerate research timelines, while simultaneously drafting a Declaration for Patient-Driven Innovation to secure structural funding and policy support. Participants concluded by identifying critical barriers in rare disease data and regulatory access, committing to a unified strategy that leverages AI and coalition-building to transform patients from subjects into primary drivers of care delivery and research agendas.
- Milken Institute1h 0m
Flipping the Script: Designing the System to Deliver for Patients
Annie Kennedy, Gigi Hirsch, Marcus Schabacker, Andy Schmeltz, Jeffrey Shuren, Marcus Wilson
Leaders from patient advocacy groups, regulators, and industry convened to address critical misalignments between regulatory data standards, payer requirements, and patient outcomes, driving a shift toward patient-led research and value-based care models. Through collaborative frameworks like FDA's Patient and Caregiver Connection and MIT's learning health systems, stakeholders are overcoming data fragmentation by integrating real-world evidence into device approvals and reimbursement decisions. This collective effort establishes a new paradigm where patient preferences directly influence benefit-risk assessments, ensuring medical innovations effectively reach the right patients at the right time while promoting equitable access.